Program Highlights Accomplishments of Company's Chief Scientific Officer and Blastomere Program
LOS ANGELES-- (BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that an ABC Television's special report titled, "Live to 150, Can You Do It? Secrets to Living Longer,” which aired last night and was hosted by Barbara Walters, highlighted the role that the company's blastomere program for creating human embryonic stem cell (hESC) lines without impacting the developmental potential of embryos could play in extending life and slowing down the aging process. The special also highlighted Advanced Cell Technology's research into developing a universal O negative red blood cell bank using human embryonic stem cell science. The report, which included an interview with Dr. Robert Lanza, MD, Chief Scientific Officer at Advanced Cell Technology, featured the company's research platforms and included a discussion of the role that the company's stem cell science could play in treating various diseases.
The show profiled the lives of several people who are currently 100 years old or older and described some of the most promising scientific developments that could extend life. Advanced Cell Technology's technology platform was included among the scientific breakthroughs.
In August 2006, Advanced Cell Technology reported in the journal Nature that company scientists had successfully generated hESCs using its blastomere technology, an approach that does not destroy the developmental potential of embryos. The blastomere technology has been reproduced and peer-reviewed on several occasions. In June 2007, ACT announced at the fifth annual meeting of the International Society for Stem Cell Research in Cairns, Australia, that it had reproduced its work by successfully producing an hESC line without destroying an embryo at its lab in Worcester, Massachusetts. In January 2008, ACT together with colleagues announced the development of five hESC lines without the destruction of embryos. The method was published in the journal Cell Stem Cells, published by Cell Press. The peer-reviewed technique was initially carried out by ACT scientists under the direction of Dr. Lanza and then independently replicated by scientists on the West Coast. In addition, the NIH announced in 2007 that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus.” ACT's blastomere program was cited by the NIH as an alternative method in its implementation plan; therefore, should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.
In addition to its blastomere research platform, Advanced Cell Technology has made progress on the therapeutic front. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. Finally, ACT's Myoblast program, an autologous adult stem cell therapy for the treatment of heart disease, has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
For more information, visit "http://www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
Daniel Schustack, 212-732-4300